Cellmid, through its wholly owned subsidiaries Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. The company holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally.
CDY Backs Hair Raising Growth for 2017 as it Capitalises on US Entry
Jan 24, 2017
Volume is a key word for life sciences play Cellmid (ASX: CDY). Its key hair loss product Evolis® aims to replace thinning hair with voluminous locks, while management seeks to volumise revenues, stock liquidity, and ultimately shareholders’ returns.
Related Cellmid (ASX:CDY) articles
From Brain Monitoring to Medical Marijuana: How Tiny BPH is Looking to Capture Fast Growing Markets
Dec 11, 2018